Omeroso drug approval chartOmeros CorporationBATS:OMERalexhalloranOMER’s near-term catalyst is an FDA decision in late December: Drug: narsoplimab (OMS721), for HSCT-associated thrombotic microangiopathy (TA-TMA). Watching levels